XENE Xenon Pharmaceuticals Inc

$XENE Xenon said it has submitted a New Drug Application to the Food and Drug Administration for azetukalner in focal seizures, moving the drug closer to a potential commercial launch in epilepsy. That leaves investors with two very different questions to weigh: how much the psychiatry setback damages azetukalner's broader opportunity and whether the epilepsy program remains intact. Xenon's depression trials hit unexpected safety problem Xenon said azetukalner's side effects were consistent with its known pharmacology and safety profile but had not emerged in its previous Phase 2 depression research. Xenon is currently assessing potential dose changes that may enhance tolerability. Drug: Azetukalner Indications affected: Major depressive disorder and bipolar depression Action: Temporary pause in new enrollment Existing patients: Remain active X-NOVA2 enrollment: About 360 patients Expected data: Q1 2027

$XENE The stock reaction is overblown given similar incidence rates of psychosis have been reported on the label of blockbuster antidepressants like Zoloft and Wellbutrin.

$XENE and some medium $RARE ribeye on deck today? Techs are solid as well. Of course any small movement from administration and the wheels are off. Lots of stuff n things out there. What are we watching today.. hmmmm. What will she like today? Hmmmmm.

$XENE she did not tell me my GME would outperform this over the past week or so. Hmmmm. At least my GME tickets are green. She still likes it apparently just not sure when it turns around!

$XENE Alrighty then. I know she still likes it otherwise she would have said. So lets get this thing cooking.

$XENE Looks like we're at the accumulation level. Flat for a while and then run. I'm long and slightly red, kind of pink so to speak.

$XENE $XENE Update: All eyes are on today's TD Cowen conference at 2:00 PM ET. While recent panic over the trial pause pushed the stock down, the core epilepsy pipeline (NDA submitted) and $1.25B in cash remain fully intact. Will management's transparency today stop the bleeding and shift focus back to fundamentals? What are your thoughts?

$XENE Bearish near-term. A company that managed to turn its own drug approval filing into a 30% crash deserves the market's suspicion, not its sympathy.

$XENE maybe its now attractive for the epilepsy asset at these prices. Trading like they have nothing else.

#INSIDERS $XENE CEO and CFO bought 45,000 shares combined at a weighted average price of $37.3587 (range $37.316 to $37.38) worth approximately $1.68 mln (transaction date 2026-09-30; Filings: 1, 2). $REX Director sold 50,000 shares at $42.5507 worth approximately $2.13 mln (transaction date 2026-09-30;

$XENE - "XENE down 30.7% on psychiatry trial pause and insider selling; downgrade and unusual volume confirm institutional bearishness." From the Top Tier Newswire AI model. The short position entry is up 7.4% as of right now.

$XENE I think till they resume MDD trails, there may not be a significant recovery. A temporary bounce / volatality is likely to trap more retails. If MDD is dicounted, the company valuation will be totally different. I am staying away for now